Is MOTS-c the same as taking an exercise supplement?

MOTS-c activates AMPK, the same metabolic sensor that exercise activates, which is why it is called an exercise mimetic. However, exercise triggers hundreds of molecular changes beyond AMPK activation. MOTS-c replicates one specific pathway, not the full spectrum of exercise benefits. It is not a replacement for physical activity.

Why do MOTS-c levels decline with age?

The exact reason is not fully understood, but it parallels the broader decline in mitochondrial function that occurs with aging. Mitochondrial DNA copy number, oxidative capacity, and production of other mitochondrial-derived peptides (like humanin) all decrease with age. MOTS-c decline may be both a marker and a contributor to age-related metabolic dysfunction.

Does MOTS-c have human clinical trial data?

Five human studies exist showing correlations between MOTS-c levels and metabolic health markers, including physical function in aging populations. Controlled interventional trials (giving exogenous MOTS-c to humans and measuring outcomes) are in early stages. PSI rates MOTS-c at Human Trials.

How does MOTS-c compare to metformin?

Both activate AMPK, but through different upstream mechanisms. Metformin inhibits mitochondrial complex I, while MOTS-c inhibits the folate-methionine cycle. Metformin has decades of clinical data and FDA approval for diabetes. MOTS-c has substantial animal data and early human correlation studies. They are not interchangeable.

What mechanism of action has been identified?

AMPK activation through a unique mechanism (folate-methionine cycle inhibition), distinct from exercise-induced AMPK activation and metformin's mechanism. The mechanistic novelty is significant because it suggests MOTS-c could complement rather than duplicate existing metabolic interventions

What does the research show about: Consistent metabolic improvements in animal models: improved insulin sensitivity?

Consistent metabolic improvements in animal models: improved insulin sensitivity, prevention of diet-induced obesity, and enhanced exercise capacity across multiple independent groups. Replication by independent research groups beyond the discovery lab strengthens the preclinical signal

What does the research show about: Five human studies confirm age-related decline in circulating MOTS-c and correla?

Five human studies confirm age-related decline in circulating MOTS-c and correlations with metabolic health markers. These studies establish that MOTS-c decline is real and measurable in humans, but correlation does not prove that supplementation will reverse the decline

What does the research show about: Nuclear translocation under metabolic stress represents a newly discovered form ?

Nuclear translocation under metabolic stress represents a newly discovered form of mitochondrial-to-nuclear communication. This retrograde signaling pathway was not previously known to involve peptide-based signals and has implications beyond MOTS-c for understanding mitochondrial biology

What does the research show about: The field is young (2015 discovery) and clinical translation from correlation to?

The field is young (2015 discovery) and clinical translation from correlation to intervention is in early stages. The rapid pace of research is encouraging, but the gap between observational human data and interventional proof remains the defining limitation

reviewed april 2026|next review october 2026|88 physicians psi has verified|194 published studies

MOTS-c

MOTS-c is a 16-amino-acid mitochondrial-derived signaling peptide encoded by the 12S rRNA gene that activates AMPK, the same master metabolic switch triggered by physical exercise, with circulating levels that decline measurably with age in humans.

Evidence landscape: 194 published studies

194 published items. 19 human studies and 132 animal studies.

19 Human
132 Animal
43 Reviews

Not FDA-approved. MOTS-c is a naturally occurring (the body's own) mitochondrial-derived peptide available as a research compound. It is not available through standard pharmacies or through specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.

194 published studies including 19 human studies and 132 animal studies. Human data is primarily correlational (measuring circulating MOTS-c levels), not interventional (giving MOTS-c to patients). Controlled interventional trials are in early stages.

Activates AMPK (the master cellular energy sensor) via folate-methionine cycle inhibition, mimicking one of the key metabolic signals produced by physical exercise. Also undergoes nuclear translocation in response to metabolic stress, representing a form of retrograde mitochondria-to-nucleus communication.

PSI Assessment

Encoded in the mitochondrial genome rather than nuclear DNA, MOTS-c is a 16-amino-acid peptide that activates the same master metabolic switch - AMPK - that physical exercise triggers. Discovered in 2015, it has rapidly become one of the most studied peptides in mitochondrial biology, with circulating levels that decline measurably with age in human cohorts. The animal data is substantial across multiple independent groups: improved insulin sensitivity, prevention of diet-induced obesity, and enhanced exercise capacity. The defining gap is that controlled interventional trials giving exogenous MOTS-c to humans are in early stages. The correlation between declining MOTS-c and declining metabolic health is documented. Whether supplementation reverses that trajectory is not yet established.

Encoded in the mitochondrial genome, not nuclear DNA. Activates the same AMPK pathway that exercise triggers. Circulating levels decline with age.

The mechanism centers on AMPK activation via folate-methionine cycle inhibition. MOTS-c inhibits the methionine-folate cycle, leading to AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) accumulation, which activates AMPK. This mimics one of the key metabolic signals produced by physical exercise. MOTS-c also undergoes nuclear translocation in response to metabolic stress, directly regulating gene expression in a form of retrograde mitochondria-to-nucleus communication that challenges the traditional view of mitochondria as passive organelles.

What the evidence supports

MOTS-c activates AMPK via folate-methionine cycle inhibition, confirmed across multiple independent groups. Circulating levels decline measurably with age in human cohorts. Animal data consistently demonstrates improved insulin sensitivity, prevention of diet-induced obesity, and enhanced exercise capacity across independent laboratories. Nuclear translocation in response to metabolic stress is documented.

What is not yet established

Whether exogenous MOTS-c administration replicates the metabolic benefits observed in animal models when given to humans. Controlled interventional trials in humans are in early stages. Optimal dosing, route, and duration for therapeutic use. Long-term safety of supraphysiological MOTS-c levels.

Research Evidence

The findings below cover what independent research groups have established and where the evidence thins for therapeutic application.

Evidence by condition

Evidence dimensions across MOTS-c research areas. Metabolic health has the deepest evidence with human correlation data. Exercise capacity and aging have consistent animal data. Neuroprotection is at the earliest stage.

Condition	Mechanism	Animal evidence	Human evidence	Replication
Metabolic Health
Exercise Capacity
Aging
Skeletal Muscle
Neuroprotection

MOTS-c activates AMPK through inhibition of the folate-methionine cycle, leading to AICAR accumulation. This is mechanistically distinct from exercise-induced AMPK activation and from metformin's mechanism (complex I inhibition). The exercise-mimetic label is grounded in shared AMPK signaling, not identical pathway activation.

The mechanistic novelty matters because it suggests MOTS-c could complement rather than duplicate existing metabolic interventions. Independent laboratories have confirmed the AMPK activation mechanism.

Circulating MOTS-c levels decline measurably with age in human cohorts. Multiple independent studies confirm this decline and correlate lower MOTS-c levels with reduced metabolic health markers and physical function in aging populations.

The age-related decline is documented across independent groups, but correlation does not establish causation. Whether MOTS-c decline drives metabolic aging or merely accompanies it is an open question.

Animal data from multiple independent groups demonstrates improved insulin sensitivity, prevention of diet-induced obesity, and enhanced exercise capacity with MOTS-c administration. Nuclear translocation under metabolic stress has been documented as a form of mitochondria-to-nucleus retrograde signaling.

Replication by independent research groups beyond the discovery laboratory strengthens the signal. The breadth of metabolic effects across different animal models is consistent.

19 Human|132 Animal|43 Reviews

View all 194 indexed studies

How MOTS-c Works

MOTS-c is a 16-amino-acid peptide, which means it is a short chain of building blocks that normally make up proteins. It is encoded by the mitochondrial genome - the DNA inside the energy-producing structures in cells - rather than the nuclear DNA that encodes most proteins.

MOTS-c works like a chemical signal that mimics what happens in your body when you exercise. It activates your cells' energy-sensing system (AMPK), which tells your body to burn more fat for fuel, use sugar more efficiently, and generally shift into a more metabolically active state. Your body produces less of it as you age, which may be one reason metabolism changes over time.

For a more detailed view of the biology, here is what researchers have observed at the molecular level.

MOTS-c is encoded within the 12S rRNA gene (MT-RNR1) of the mitochondrial genome, making it one of the first identified mitochondrial-derived peptides (MDPs). Its mechanism of AMPK activation is indirect: MOTS-c inhibits the de novo purine biosynthesis pathway at the folate cycle level, leading to accumulation of the AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). Under metabolic stress, MOTS-c translocates from mitochondria to the nucleus, where it interacts with antioxidant response elements (ARE/EpRE) to modulate expression of genes involved in metabolic adaptation. This retrograde mitochondria-to-nucleus signaling was not previously known to involve peptide-based signals.

What is MOTS-c being studied for?

Researchers are studying MOTS-c across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for MOTS-c overall. This means a compound can have human studies for one condition but only animal data for another.

Metabolic Health

·Human Trials

Animal studies consistently show MOTS-c improves insulin sensitivity and reduces diet-induced obesity. Human correlation studies link MOTS-c levels to metabolic health markers.

Limitations: Human data is correlational, not interventional. No controlled trial has demonstrated that exogenous MOTS-c administration improves metabolic markers in humans.

Exercise Capacity

·Animal Studies

MOTS-c enhances exercise capacity in animal models and is released during physical activity in both mice and humans.

Limitations: Exercise capacity improvements are demonstrated in mice only. Whether exogenous MOTS-c enhances human exercise performance has not been tested.

Aging

·Animal Studies

Circulating MOTS-c levels decline with age in humans. Animal data suggests supplementation may counter age-related metabolic decline.

Limitations: The observation that MOTS-c declines with age does not establish that restoring levels will reverse aging processes. No interventional aging study has been conducted.

Skeletal Muscle

·Animal Studies

Animal studies show MOTS-c administration improves skeletal muscle metabolism and function in aged mice.

Limitations: All muscle function data is from animal models. Human studies have not tested whether MOTS-c improves skeletal muscle function.

Neuroprotection

·Preclinical

Very early research suggests MOTS-c may have neuroprotective properties, but the evidence is minimal.

Limitations: Extremely limited data. No dedicated neuroprotection studies. Any neuroprotective claims are speculative extrapolations from the general metabolic mechanism.

Safety and Regulatory Status

FDA Status: Not FDA-approved for any indication. MOTS-c is a naturally occurring (the body's own) mitochondrial-derived peptide. No regulatory agency has evaluated MOTS-c for therapeutic use.

Availability: Available as a research compound from peptide suppliers. Not available through standard pharmacies or specialty pharmacies where a licensed pharmacist prepares a medicine from ingredients for an individual patient.

Class context: MOTS-c is part of the mitochondrial-derived peptide (MDP) family alongside humanin. Circulating levels decline with age. Animal studies show favorable safety at therapeutic doses. Human safety data from interventional studies is very limited.

As a naturally occurring (the body's own) peptide, MOTS-c has a baseline safety context. Animal studies at therapeutic and supratherapeutic doses have not reported significant adverse effects. The metabolic mechanism (AMPK activation) is well-understood and shared with exercise and metformin. Human safety data from interventional studies is very limited.

Peptide Structure

Technical molecular data for researchers and clinicians.

Questions and Comparisons

Questions the evidence raises for a MOTS-c discussion.

Comparison and Related Research

MOTS-c is most often compared with other mitochondrial-targeting peptides. The comparisons below outline how each differs in mechanism, evidence base, and clinical development.

Head-to-head comparisons

Full research comparisons covering MOTS-c and another peptide side by side.

MOTS-c vs SS-31 (Elamipretide)

Both target cellular energy production. MOTS-c is a metabolic regulator. SS-31 protects mitochondrial membranes. Evidence-graded comparison.

View full comparison

MOTS-c vs Humanin

Both encoded by mitochondrial DNA. MOTS-c targets metabolism. Humanin targets cell survival. Evidence-graded comparison of mitochondrial-derived peptides.

View full comparison

Related compounds

SS-31 (Elamipretide)Humanin Epitalon 5-Amino-1MQ FOXO4-DRI

Frequently Asked Questions

References

Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.

1.The discovery paper identifying MOTS-c as a novel mitochondrial-derived peptide encoded within the 12S rRNA gene. In mouse models, MOTS-c administration prevented age-dependent and high-fat-diet-induced insulin resistance and obesity. This study established MOTS-c as the first mitochondrial-encoded peptide with systemic metabolic signaling activity.Lee C et al., 2015 in Cell Metab. View on PubMed
2.Demonstrated that MOTS-c is an exercise-responsive peptide whose levels increase in skeletal muscle and plasma following physical activity. In aged mice, MOTS-c treatment improved physical capacity and muscle homeostasis. The study also showed that MOTS-c translocates to the nucleus and regulates gene expression related to cellular stress adaptation.Reynolds JC et al., 2021 in Nat Commun. View on PubMed
3.Examined how mitochondrial-derived peptides including MOTS-c and humanin modulate mitochondrial function in the context of cellular aging. Found that these peptides regulate metabolic pathways associated with senescence, providing evidence that mitochondrial-encoded signaling molecules play a role in age-related metabolic decline.Kim SJ et al., 2018 in Aging (Albany NY). View on PubMed
4.Measured MOTS-c expression in skeletal muscle biopsies from healthy men across different age groups. Found that MOTS-c levels were higher in older participants and correlated with the proportion of type I (slow-twitch) muscle fibers, suggesting a compensatory increase in MOTS-c signaling during aging.D'Souza RF et al., 2020 in Aging (Albany NY). View on PubMed

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.